(Q35621686)

9 August 2017

1 reference

title

Hepatitis B viral resistance: mechanisms and diagnosis (English)

1 reference

9 August 2017

1 reference

Stephen Locarnini

1

1 reference

9 August 2017

1 January 2003

1 reference

9 August 2017

Journal of Hepatology

1 reference

9 August 2017

39 Suppl 1

1 reference

9 August 2017

S124-32

1 reference

The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B.

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Dynamics of hepatitis B virus infection in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

The clinical significance of molecular variation within the hepatitis B virus genome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Mutation rate of the hepadnavirus genome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

On the Origin of Species

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

HBx gene of hepatitis B virus induces liver cancer in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Generation of replication-competent hepatitis B virus nucleocapsids in insect cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Low dynamic state of viral competition in a chronic avian hepadnavirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Hepatitis B virus biology

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Inhibition of duck hepatitis B virus DNA replication by antiviral chemotherapy with ganciclovir-nalidixic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Clinical experience with famciclovir against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Identification of four conserved motifs among the RNA-dependent polymerase encoding elements

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Primary infection with a lamivudine-resistant hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

Global status of hepatitis B immunisation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

RNA virus populations as quasispecies.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900318-0

7 January 2021

10.1016/S0168-8278(03)00318-0

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14708690